Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2726-2731

  Hoang Xuan, K ^a   Taillandier, L ^a   Chinot, O ^a   Soubeyran, P ^a   Bogdhan, U ^a   Hildebrand, J ^a   Frenay, M ^a   De Beule, N ^a   Delattre, J Y ^a   Baron, B ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; LYMPHOMA; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; AGE; BELGIUM; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; RESEARCH; RISK ASSESSMENT; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; BIOPSY, NEEDLE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SPINAL; LOMUSTINE; LYMPHOMA; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROCARBAZINE; RESEARCH; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0043132268     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.036     Document Type: Article

References (18)

1. Coté TR, Manns A, Hardy CR, et al: Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 88:675-679, 1996
2. Corn BW, Sue MM, Topham A, et al: Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79:2409-2413, 1997
3. De Angelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992
4. Blay JY, Bouhour D, Carrie C, et al: The C5R protocol: A regimen of high dose chemotherapy and radiotherapy in primary cerebral non Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 86:2922-2929, 1995
5. O'Brien P, Roos D, Pratt G, et al: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519-526, 2000
6. Bessel EM, Graus F, Lopez-Guillermo A, et al: CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 50:457-464, 2001
7. Abrey LE, De Angelis L, Yahalom J: Long term survival in primary central nervous system lymphoma. J Clin Oncol 16:859-863, 1998
8. Nelson DF, Martz K, Bonner H, et al: Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG)-RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992
9. Corry J, Smith JG, Wirth A, et al: Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41:615-620, 1998
10. Schultz C, Scott C, Sherman W, et al: Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD) for PCNSL: Initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. J Clin Oncol 14:556-564, 1996
11. O'Neill BP, Wang CH, O'Fallon JR, et al: Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-42. Int J Radiat Oncol Biol Phys 23:559-563, 1999
12. Desablens B, Gardembas M, Haie-Meder C, et al: Primary CNS lymphoma: Long term results of the GOELAMS LCP88 trial with a focus on neurological complications among 152 patients. Ann Oncol 10:14, 1999 (suppl 3, abstr)
13. De Angelis L, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002
14. Freilich RJ, Monjour A, Delattre JY, et al: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435-440, 1996
15. Abrey LE, Yahalom J, De Angelis L: Treatment of primary CNS lymphoma: The next step. J Clin Oncol 18:3144-3150, 2000
16. Siobhan NG, Rosenthal MA, Ashley D, et al: High dose methotrexate for primary CNS lymphoma in the elderly. Neuro-oncol 2:40-44, 2000
17. McAllister LD, Doolittle ND, Guastadisegni PE, et al: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51-60, 2000
18. Soussain C, Suzan F, Hoang-Xuan K, et al: Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or first relapse primary central nervous system lymphoma or intraocular lymphoma. J Clin Oncol 19:742-749, 2001